About Genable Technologies
Genable Technologies is a Healthcare company based in Dublin (Ireland) founded in 2001 by Paul Kenna and Jane Farrar, and was acquired by Spark Therapeutics in March 2016. Gene therapy for Retinitis pigmentosa is developed using AAV vectors. Genable Technologies has raised $8.11 million across 2 funding rounds from investors including Spark Therapeutics, Fountain Healthcare Partners and Delta Partners. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics.
Company details
Provider of gene therapy to treat Retinitis pigmentosa. The first gene medicine - RhoNova formerly known as GT038 - is for the treatment of patients with rhodopsin (RHO)-linked adRP - a debilitating form of inherited blindness resulting from a diverse array of mutations in the RHO gene. It utilizes AAV vectors to obtain expression of RNA interference (RNAi) molecules which suppress the expression of both the faulty and normal gene copies and replaces this with a gene subtly altered to become refractory to suppression but still encoding a normal wild type protein.
- Headquarters Dublin, Ireland
- Founders Paul Kenna, Jane Farrar
- Stage Acquired
- SectorsHealthcare
- Website genable.net
- Social LinkedIn
- Acquired by Spark Therapeutics (Mar 2016)
- Total Equity Funding$8.11M (USD)
in 2 rounds
- Latest Funding Round$6.78M (USD), Series B
Nov 2011
- InvestorsSpark Therapeutics
& 2 more
- Acquired bySpark Therapeutics
(Mar 2016)
Funding Insights of Genable Technologies
Genable Technologies has successfully raised a total of $8.11M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $6.78 million completed in November 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.11M
- Total Rounds 2
- Last Round Series B — $6.78M
- First Round $1.33M
(Sep 2004)
- Investors Count 2
All 2 funding rounds of Genable Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2011 | $6.78M | Series B | – | – | |
| Sep 2004 | $1.33M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Genable Technologies
Genable Technologies has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Spark Therapeutics, Fountain Healthcare Partners and Delta Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Risk capital is provided to life sciences entrepreneurs. | fh-partners.com | Dublin, Ireland | ||
Early stage venture capital is provided to Irish startups. | deltapartners.com | Ireland | ||
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | sparktx.com | Philadelphia, United States |
Investor details for Genable Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genable Technologies
2 people are tracked at Genable Technologies (2 in leadership).
| Name | Role | Group |
|---|---|---|
Paul Kenna | Co-Founder | Leadership |
Jane Farrar | Co-Founder | Leadership |
Complete people profiles for Genable Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Genable Technologies
4 dated milestones of Genable Technologies across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Genable Technologies is founded.
- Funding First funding round of $1.3M.
- Funding Latest funding round, Series B, of $6.8M.
- Exit Acquired by Spark Therapeutics.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genable Technologies
Complete news archive for Genable Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genable Technologies
Genable Technologies was founded in 2001 and raised its 1st funding round 3 years after it was founded.
Genable Technologies is headquartered in Dublin, Ireland.
Genable Technologies is a funded company, having raised a total of $8.11M across 2 funding rounds to date. The company's 1st funding round was a Series A of $1.33M, raised on Sep 2004.
Provider of gene therapy to treat Retinitis pigmentosa. The first gene medicine - RhoNova formerly known as GT038 - is for the treatment of patients with rhodopsin (RHO)-linked adRP - a debilitating form of inherited blindness resulting from a diverse array of mutations in the RHO gene. It utilizes AAV vectors to obtain expression of RNA interference (RNAi) molecules which suppress the expression of both the faulty and normal gene copies and replaces this with a gene subtly altered to become refractory to suppression but still encoding a normal wild type protein.
Genable Technologies has 3 investors. Key investors include Spark Therapeutics, Fountain Healthcare Partners, and Delta Partners.
Yes. Genable Technologies was acquired by Spark Therapeutics in March 2016.